van Kol Kim, Ebisch Renée, Piek Jurgen, Beugeling Maaike, Vergeldt Tineke, Bekkers Ruud
Department of Obstetrics and Gynecology and Catharina Cancer Institute, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands.
Department of Obstetrics and Gynecology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center+, 6229 ER Maastricht, The Netherlands.
Cancers (Basel). 2021 Dec 8;13(24):6190. doi: 10.3390/cancers13246190.
To determine the incidence of pathology-proven residual disease in adjuvant hysterectomy specimens in patients with cervical cancer, treated with chemoradiation therapy. Secondly, to assess a possible association for pathology-proven residual disease regarding the time between chemoradiation therapy and adjuvant hysterectomy. Additionally, the survival rate and complication rate were assessed.
PubMed, EMBASE, and the Cochrane database were searched from inception up to 8 March 2021.
Of the 4601 screened articles, eleven studies were included. A total of 1205 patients were treated with chemoradiation therapy and adjuvant hysterectomy, ranging from three to twelve weeks after chemoradiation therapy. A total of 411 out of 1205 patients (34%) had pathology-proven residual disease in the adjuvant hysterectomy specimen. There was no association found in the time between chemoradiation therapy and adjuvant hysterectomy. Follow-up ranged from 2.4 to 245 months, during which 270 patients (22%) relapsed, and 298 patients (27%) were deceased. A total of 202 (35%) complications were registered in 578 patients.
there is no association found in the time between chemoradiation therapy and residual disease on adjuvant hysterectomy specimens. The survival rates after chemoradiation therapy and adjuvant hysterectomy are suboptimal, while the risk of complications after adjuvant hysterectomy is high.
确定接受放化疗的宫颈癌患者辅助性子宫切除标本中病理证实的残留病灶发生率。其次，评估病理证实的残留病灶与放化疗和辅助性子宫切除之间时间间隔的可能关联。此外，评估生存率和并发症发生率。
检索了从创刊至2021年3月8日的PubMed、EMBASE和Cochrane数据库。
在筛选的4601篇文章中，纳入了11项研究。共有1205例患者接受了放化疗和辅助性子宫切除，时间间隔为放化疗后3至12周。1205例患者中共有411例（34%）在辅助性子宫切除标本中有病理证实的残留病灶。未发现放化疗与辅助性子宫切除之间的时间间隔存在关联。随访时间为2.4至245个月，在此期间270例患者（22%）复发，298例患者（27%）死亡。578例患者中共有202例（35%）出现并发症。
放化疗与辅助性子宫切除标本中的残留病灶之间的时间间隔未发现关联。放化疗和辅助性子宫切除后的生存率不理想，而辅助性子宫切除后的并发症风险较高。
